1 March 2023 in Protein & Peptide Letters
Background: The DNA polymerase of Thermus thermophilus (Tth pol) presents reverse transcriptase activity with Mn2+, and can be used for one-step RT-qPCR. However, Mn2+ would reduce amplification fidelity and cause nonspecific products. Objective: Eliminating the Mn2+ dependence of the reverse transcriptase activity of Tth pol by point mutations. Methods: We constructed three variants I640F, I709K, and I640F/I709K, and measured their DNA polymerase and reverse transcriptase activities without Mn2+. Their enzymatic characteristics and PCR inhibitor resistance were also tested. Finally, these variants were applied in one-step RT-qPCR. Results: All three variants presented reverse transcriptase activity with Mg2+ only and increased DNA polymerase activity. The variants, except I709K, showed no significant difference in thermostability, optimal pH, optimal NaCl concentration, storage stability and PCR inhibitor resistance compared to the wild type. Variant I640F/I709K had good performance in one-step RT-qPCR with Mg2+ only, whereas both variants with single substitution exhibited nonspecific amplification. Conclusion: We successfully constructed three Tth pol variants possessing Mn2+ independent reverse transcriptase activity. The variant I640F/I709K was suitable for one-step RT-qPCR because of its good performance.
28 January 2021 in RNA Biology
Regulation of gene expression starts from the transcription initiation. Regulated transcription initiation is critical for generating correct transcripts with proper abundance. The impact of epigenetic control, such as histone modifications and chromatin remodeling, on gene regulation has been extensively investigated, but their specific role in regulating transcription initiation is far from well understood. Here we aimed to better understand the roles of genes involved in histone H3 methylations and chromatin remodeling on the regulation of transcription initiation at a genome-scale using the budding yeast as a study system. We obtained and compared maps of transcription start site (TSS) at single-nucleotide resolution by nAnT-iCAGE for a strain with depletion of MINC (Mot1-Ino80C-Nc2) by Mot1p and Ino80p anchor-away (Mot1&Ino80AA) and a strain with loss of histone methylation (set1Δset2Δdot1Δ) to their wild-type controls. Our study showed that the depletion of MINC stimulated transcription initiation from many new sites flanking the dominant TSS of genes, while the loss of histone methylation generates more TSSs in the coding region. Moreover, the depletion of MINC led to less confined boundaries of TSS clusters (TCs) and resulted in broader core promoters, and such patterns are not present in the ssdΔ mutant. Our data also exhibits that the MINC has distinctive impacts on TATA-containing and TATA-less promoters. In conclusion, our study shows that MINC is required for accurate identification of bona fide TSSs, particularly in TATA-containing promoters, and histone methylation contributes to the repression of transcription initiation in coding regions.
17 September 2026 in SSRN Electronic Journal
Therapeutic technologies often show recurring stages of product formation, generational renewal, independent confirmation, and subsequent expansion, but the time required for these transitions varies substantially across lineages and modalities. Using small molecules as a historical calibration domain and product-level therapeutic histories, this study measures the interval from the first viable lineage-forming product (P1) to the first materially upgraded generation (G2), and from G2 to the first independent product confirming the reproducibility of that generation (C2). Across smallmolecule lineages, P1→G2 intervals range from approximately four decades in some early lineages to 5-6 years in several later ones. However, substantial variation among lineages arising under similar pharmaceutical R&D conditions indicates that calendar era and system maturity alone do not fully explain the differences in maturation timing. G2→C2 intervals are generally much shorter than P1→G2. Among newer therapeutic modalities, observed P1→G2 intervals range from 11 to 15 years, whereas completed G2→C2 intervals are also substantially shorter. These patterns are consistent with differences in the capabilities available at P1 and the technological challenges that remain before a materially upgraded generation can emerge.